S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2- carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma

Melanoma Research

Volumn 7, Issue 5, 1997, Pages 393-399

  Karnell R ^a   Von Schoultz, E ^a   Hansson, L O ^a   Nilsson, B ^a   Arstrand K ^b   Kagedal B ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 S cysteinyldopa; 6 hydroxy 5 methoxyindole 2 carboxylic acid; Malignant melanoma; S100B protein; Tumour markers

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; SKIN BIOPSY; URINALYSIS;

EID: 0030663652     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199710000-00005     Document Type: Article

References (39)

1. Cancer Incidence in Sweden 1991. The National Board of Health and Welfare, Center for Epidemiology, Stockholm, 1994.
2. Prota G. Structure and biogenesis of phaeomelanins. In: Riley V, ed. Pigmentation: its Genesis and Biologic Control. New York: Appleton-Century-Crofts, Meredith Co., 1972: 615-630.
3. Prota G. Recent advances in the chemistry of melanogenesis in mammals. J Invest Dermatol 1980; 75: 122-127.
4. Rorsman H, Agrup G, Hansson C, Rosengren E. Biochemical recorders of malignant melanoma. In: MacKie RM, ed. Pigment Cell. Basel: Karger, 1983; 6: 93-115.
5. Ito S. Melanin-related metabolites as markers of melanoma: a review. J Dermatol 1992; 19: 802-805.
6. Agrup G, Agrup R Andersson T, Hafström L, Hansson C, Jakobsson S, Jönsson P-E, Rorsman H, Rosengren A-M, Rosengren E. 5 Years' experience of 5-S-cysteinyl-dopa in melanoma diagnosis. Acta Derm Venereol 1979; 59: 381-388.
7. Peterson LL, Woodward WR, Fletcher WS, Palmquist M, Tucker MA, Ilias A. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic naevus syndrome and normal subjects. J Am Acad Dermatol 1988; 19: 509-515.
8. Nimmo JOE, Gawkrodger DJ, O'Docherty CStJ, Going SM, Percy-Robb IW, Hunter JAA. Plasma 5-S-cysteinyldopa as an index of melanogenesis. Br J Dermatol 1988; 118: 487-496.
9. Pavel S, Muskiet FAJ. Eumelanin (precursor) metabolites as markers for pigmented malignant melanoma: a preliminary report. Cancer Detect Prevent 1983; 6: 311-316.
10. Pavel S, Elzinga H, Muskiet FAJ, Smit JM, Mulder NH, Schraffordt Koops H. Eumelanin-related indolic compounds in the urine of treated melanoma patients. J Clin Chem Clin Biochem 1986; 24: 167-173.
11. Hara H, Walsh N, Yamada K, Jimbow K. High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxy-indole-2-carboxylic acid as a prognostic marker for malignant melanoma. J Invest Dermatol 1994; 102: 501-505.
12. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19: 739-744.
13. Donato R. Perspectives in S100B protein biology. Review article. Cell Calcium 1991; 12: 713-726.
14. Kligman D, Hilt DC. The S100 protein family. Trends in Biochem Sci 1988; 13: 437-443.
15. Isobe T, Okuyama T. The amino-acid sequence of S100B protein (PAP I-b protein) and its relation to calcium-binding proteins. Eur J Biochem 1978; 89: 379-388.
16. 2+-induced disassembly of brain microtubule proteins in vitro. FEBS Lett 1982; 147: 165-167.
17. Takahashi K, Isobe T, Ohtsuki Y et al. Immunohisto-chemical localization and distribution of S100 proteins in the human lymphoreticular system. Am J Pathol 1984; 116: 497-503.
18. Nakajima T, Sato Y, Watanabe S et al. Immunoelectron microscopical demonstration of S100 protein in epidermal Langerhans' cells. Biomed Res 1982; 3: 226-231.
19. Persson L, Hårdemark H-G, Gustavsson J, Rundström G, Mendel-Hartvid I, Esscher T, Påhlman S. S100B protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987; 18: 911-918.
20. Gatter KC, Ralfkiaer E, Skinner J, Brown D, Heryet A, Pulford KAF, Hou-Jensen K, Mason DY. An immuno-cytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours. J Clin Pathol 1985; 38: 1353-1357.
21. Carrel S, Rimoldi D. Melanoma-associated antigens. Eur J Cancer 1993; 29A: 1903-1907.
22. Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal anti-bodies against S100B subunits. Cancer 1990; 66: 765-771.
23. von Schoultz E, Hansson LO, Djureen E, Hansson J, Kärnell R, Nilsson B, Stigbrand T, Ringborg U. Prognostic value of serum analyses of S-100β protein in malignant melanoma. Melanoma Res 1996; 6: 133-137.
24. Bei Guo H, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995; 31A: 1898-1902.
25. Ketcham AS, Moffat FI, Balch CM. Classification and staging. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, eds. Cutaneous Melanoma (2nd edn), Philadelphia: JB Lippincott, 1992; 213-220.
26. Kågedal B, Källberg M, Årstrand K, Hansson C. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urine. J Chromatogr 1989; 473: 359-370.
27. Pavel S, van der Slik W. Analysis of eumelanin-related indolic compounds in urine by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 1986; 375: 392-398.
28. Kågedal B, Lenner L, Årstrand K, Hansson C. The stability of 5-S-cysteinyldopa and 6-hydroxy-5-methoxy-indole-2-carboxylic acid in human urine. Pigment Cell Res 1992; 2(suppl): 304-307.
29. Nyberg L, Urdal P, Skogseid IM, Nordby H, Bnmdell J. S100B in human serum as a marker for brain damage. The 15th Meeting of the European Neuroscience Association, Munich, Germany, 1992.
30. Cox DR. Regression models and life-tables (with discussion). J Royal Statist Soc 1972; B34: 187-220.
31. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-38.
32. Hornef S, Lux J, Rassner G. Neuronen-spezifische Enolase (NSE) - ein geeigneter Tumormarker des malignen Melanoms? Hautarzt 1992; 43: 77-80.
33. Couvreur R, Joos G, Geerts M-L, Lambert J, Naeyaert J-M. Neuron-specific enolase as serum marker for malignant melanoma. Lancet 1993; 342: 985-989.
34. Schutter EMJ, Visser JJ, van Kamp GJ, Mensdorff-Pouilly S, van Dijk W, Hilgers J, Kenemans P. The utility of lipid-associated sialic acid (IASA or LSA) as a serum marker for malignancy. A review of the literature. Tumour Biol 1992; 13: 121-132.
35. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-1229.
36. Sonesson B, Eide S, Ringborg U, Rorsman H, Rosengren E. Tyrosinase activity in the serum of patients with malignant melanoma. Melanoma Res 1995; 5: 113-116.
37. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73: 629-636.
38. Smoller BR. Immunohistochemistry in the diagnosis of malignant melanoma. Clin Dermatol 1991; 9: 235-241.
39. Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence JJ. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100B-binding protein. Proc Natl Acad Sci USA 1992; 89: 11627-11631.